Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

General Fusion to Showcase Practical Path to Commercial Fusion Energy and Future Public Listing at Major Energy Conferences 7-04-2026, 20:00

RLF Communications Expands North Carolina Footprint With 8-02-2023, 22:08